5-HIAA urine test

Definition

5-HIAA is a urine test that measures the amount of 5-hydroxyindoleacetic acid (5-HIAA). 5-HIAA is a breakdown product of a hormone called serotonin.

This test tells how much 5-HIAA the body is producing, which reflects how much serotonin is in the body.

Alternative Names

HIAA; 5-hydroxyindole acetic acid; Serotonin metabolite

How the Test is Performed

A 24-hour urine sample is needed. You'll need to collect your urine over 24 hours in a container provided by the lab. Your health care provider will tell you how to do this. Follow instructions exactly.

How to Prepare for the Test

Your provider will instruct you, if necessary, to stop taking medicines that may interfere with the test.

Medicines that can increase 5-HIAA measurements include acetaminophen (Tylenol), acetanilide, phenacetin, glyceryl guaiacolate (found in many cough syrups), methocarbamol, and reserpine.

Medicines that can decrease 5-HIAA measurements include heparin, isoniazid, levodopa, monoamine oxidase inhibitors, methenamine, methyldopa, phenothiazines, and tricyclic antidepressants.

You will be told not to eat certain foods for 3 days before the test. Foods that can interfere with 5-HIAA measurements include plums, pineapples, bananas, eggplant, tomatoes, avocados, and walnuts.

How the Test will Feel

The test involves only normal urination, and there is no discomfort.

Why the Test is Performed

This test measures the level of 5-HIAA in the urine. It is often done to detect certain tumors in the digestive tract (carcinoid tumors) and to track the progress of a person with a carcinoid tumor.

Normal Results

The normal range is 2 to 9 mg/24h (10.4 to 46.8 µmol/24h).

Normal value ranges may vary slightly among different lab. Some labs use different measurements or test different samples. Talk to your provider about the meaning of your specific test results.

What Abnormal Results Mean

Abnormal results may be due to:

Risks

There are no risks with this test.

References

Riley RS, McPherson RA. Basic examination of urine. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Philadelphia, PA: Elsevier; 2022:chap 29.

Wolin EM, Jensen RT. Neuroendocrine neoplasms. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 213.


Review Date: 8/21/2024
Reviewed By: Warren Brenner, MD, Oncologist, Lynn Cancer Institute, Boca Raton, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, timeliness, or correctness of any translations made by a third-party service of the information provided herein into any other language. © 1997- A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
© 1997- adam.comAll rights reserved.